Refractory Generalised Myasthenia Gravis (gMG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Refractory Generalised Myasthenia Gravis (gMG) Market Outlook

Thelansis’s “Refractory Generalised Myasthenia Gravis (gMG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Refractory Generalised Myasthenia Gravis (gMG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Refractory Generalised Myasthenia Gravis (gMG) Overview

Myasthenia gravis (MG) is a clinically heterogeneous autoimmune disorder affecting the neuromuscular junction. It is characterized by fatigable weakness of voluntary muscles. The onset of MG can occur at any age, but in the adult-onset form, there is a bimodal peak. Generalized MG, which commonly affects women under the age of 40, has a higher prevalence than in men. Men, on the other hand, are more likely to develop MG after the age of 60. The underlying cause of MG is autoimmune in nature. Self-reactive antibodies target acetylcholine receptors, which are crucial for facilitating muscle contraction and movement. However, approximately 15% of individuals with generalized MG do not have antibodies against acetylcholine receptors. Instead, these patients possess self-reactive antibodies against other important molecules involved in nerve-muscle communication, such as muscle-specific kinase (MuSK). Nearly all patients who develop generalized MG do so within two or three years after the initial display of symptoms. The exact pathogenesis of MG remains unknown. However, it is associated with circulating antibodies against various muscle receptors, including acetylcholine receptor (AChR) and muscle-specific receptor tyrosine kinase (MuSK). Another targeted molecule, the low-density lipoprotein receptor-related protein 4 (LRP4), has also been identified. The thymus is believed to trigger the production of antibodies against AChR in certain forms of the disease. These antibodies are known to have a pathogenic role in all forms of MG. Drug-induced MG can occur due to the use of medications such as D-penicillamine, interferon alpha, or as a result of bone marrow transplantation. In some cases, an initial infection (EBV) may be responsible for the development of MG. Muscle weakness is the primary manifestation of MG. Approximately 85% of patients experience generalized myasthenia gravis, which affects the proximal muscles of the extremities and trunk. Generalized MG (gMG) treatments include thymectomy, immunosuppressive therapies, intravenous immunoglobulins, and plasmapheresis.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Refractory Generalised Myasthenia Gravis (gMG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034